VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Overview Fund Activity
Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

67 hedge funds and large institutions have $124M invested in Viracta Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 8 closing their positions.

Holders
67
Holders Change
+5
Holders Change %
+8.06%
% of All Funds
1.18%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
19
Reduced
15
Closed
8
Calls
$497K
Puts
$673K
Net Calls
-$176K
Net Calls Change
-$100K

Top Buyers

1
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$8.57M
2
ASP
2
Adams Street Partners
Illinois
$5.85M
3
JPMorgan Chase & Co
3
JPMorgan Chase & Co
New York
$4.63M
4
Blackstone Inc
4
Blackstone Inc
New York
$1.91M
5
State Street
5
State Street
Massachusetts
$4.63M

Top Sellers

1
SAM
1
Sectoral Asset Management
Quebec, Canada
$0
2
KHCM
2
Kettle Hill Capital Management
New York
$0
3
B
3
Bailard
California
$401K
4
Goldman Sachs
4
Goldman Sachs
New York
$1.37M
5
Janus Henderson Group
5
Janus Henderson Group
United Kingdom
$2M
Name Market Value Shares Shares
Change 		Shares
Change %
PA
76
Parallel Advisors
California
$0 8 – –
BWP
77
Baldwin Wealth Partners
Massachusetts
$0 47 – –
1 2 3
4